Trevi Therapeutics (NASDAQ:TRVI) Releases Earnings Results

On Tuesday, Trevi Therapeutics (NASDAQ:TRVI) announced its latest earnings results for the quarter. The company reported an earnings per share (EPS) of ($0.11), which was better than analysts' expectations of ($0.12) by $0.01, according to Zacks.

Trevi Therapeutics Stock Movement

Following the announcement, Trevi Therapeutics shares rose by 0.8%, trading up $0.06 to reach $6.60. During the trading session, the volume was reported at 2,202,888 shares, surpassing the average volume of 968,847. Currently, Trevi Therapeutics has a market cap of $506.93 million and a price-to-earnings ratio of -14.99, with a beta of 0.90. Over the past year, the company’s stock has seen a low of $2.30 and a high of $7.39. The fifty-day moving average stands at $4.39 while the 200-day moving average is at $3.66.

Insider Transactions

In related news, insider Farrell Simon sold 81,313 shares of Trevi Therapeutics stock on March 10. The shares were sold at an average price of $6.75, totaling $548,862.75. After this transaction, Simon holds 76,900 shares valued at approximately $519,075, marking a decrease of 51.39% in his ownership. This transaction has been documented in a filing with the Securities and Exchange Commission.

Analyst Ratings

Trevi Therapeutics has garnered attention from several research analysts. Oppenheimer raised their target price for the stock from $12.00 to $20.00 and assigned an "outperform" rating on March 11. HC Wainwright increased their price target from $7.50 to $12.50, giving the stock a "buy" rating. Additionally, Needham & Company lifted their target price from $8.00 to $25.00 with a "buy" rating. D. Boral Capital maintained a "buy" rating with a new target of $21.00. Similarly, Raymond James upgraded the stock from "outperform" to "strong-buy", raising their target from $9.00 to $29.00. Currently, seven research analysts recommend buying the stock while three analysts have given it a strong buy rating. The consensus rating for Trevi Therapeutics is "Buy" with an average target price of $15.94, as per MarketBeat data.

Overview of Trevi Therapeutics

Trevi Therapeutics, Inc. is a biopharmaceutical company in the clinical stage that focuses on developing and commercializing its therapy, Haduvio. This therapy aims to treat chronic cough associated with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), targeting both the central and peripheral nervous systems.

Final Thoughts

Investors looking at Trevi Therapeutics may want to watch for future developments and analyst ratings as the company progresses with its therapeutic initiatives.

earnings, stocks, analysis